

Corgenix CFO to Appear on Market News First Live Interview on Friday, July 13, 2007 at 11:00 AM EDT

Thursday July 12, 8:33 am ET

DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: [CONX](#) - [News](#)), a worldwide developer and marketer of diagnostic test kits, announced that its Chief Financial Officer, Bill Critchfield, will appear on Market Network News (mn1.com) on Friday, July 13, 2007 at 11:00 AM EDT (9:00 AM MST).

Mr. Critchfield will provide a brief corporate overview of the Company, as well as give an update on new developments, including the recent FDA approval of AspirinWorks®, the Company's newest diagnostic test kit. "With more than one million Americans experiencing new or recurrent heart attacks each year, we believe AspirinWorks is important to the health of millions in the U.S., in addition to the rest of the world. Its approval is an enormous milestone for our Company," said Critchfield.

At risk individuals are eligible for aspirin therapy and should be tested for the presence or absence of the therapy's effect. The AspirinWorks Test Kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion.

About <http://www.mn1.com/>

Market News First is an online, market news provider that brings investors current news on the market. Market News First is the only online, live IPTV web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE. Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans. Market News First, "News You Can Trust." <http://www.mn1.com/>.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Contact:

Corgenix Medical Corp.
William Critchfield, 303-453-8903

Senior VP and CFO

wcritchfield@corgenix.com

or

Investors:

The Investor Relations Group

Dian Griesel/ Erika Moran, 212-825-3210

Fax: 212-825-3229

or

Media:

Armada Medical Marketing

Dan Snyders, 303-623-1190 x 230

Vice President, Public Relations Supervisor

Fax: 303-623-1191

dan@armadamedical.com